ACL's Principal Activity is the provision of pathology services.
|Bid / Ask||-|
|Volume (4w avg)|
|vs Sector (1yr)||-|
|vs ASX 200 (1yr)||-25.17%|
|ASX Rank||344 of 2,295|
|NTA per share||$0.00|
ACL is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.
Australian Clinical Labs Limited (ACL) is a private provider of pathology services in Australia. ACL's mission is to combine talented people, medical and scientific leadership, with innovative thinking and technologies to empower decision making that saves and improves patients' lives. It is servicing over 90 private and public hospitals.
No incorporation details available.
DPS and Yield calculations use the Pay Date.
|No dividends paid.|
See Upcoming Dividends for all ASX companies.
|Dr Michael Philip Stanford||Non-Executive Director||Apr 2021||
Dr Michael Philip Stanford
Dr Stanford has over 25 years of Non-Executive Director experience across a range of industries including healthcare services, diagnostics, biotech, pharmaceutical, property, aged care and higher education. Michael is the current Chair of Diabetes Australia, an Independent Non-Executive Director of NorthWest Healthcare Property Management Limited and Nucleus Network Limited, and a Senior Advisor at Medibank Private Limited. Michael's former roles include Non-Executive Director for ACL between 2016 and 2019, Healthscope Limited, Virtus Health Limited, and Deputy Chancellor of Curtin University. He was in Group Chief Executive Officer roles for 23 years including 16 years at St John of God Health Care. He was also formerly a specialist in public health medicine.
|Dr Leanne Rowe||Non-Executive Director||Apr 2021||
Dr Leanne Rowe
Dr Rowe has over 30 years of clinical experience in the public and private health systems across acute care, aged care, mental health and community health. Leanne is currently Chair of Nexus Hospitals and a Non-Executive Director of Japara Healthcare Limited, Doctor Care Anywhere Group PLC, the Medical Indemnity Protection Society and MIPS Insurance. Previously she was Chair of the Royal Australian College of General Practitioners and a Non-Executive Director of Medibank Private, I-MED Radiology Network, GMHBA, Australian Health Management, Barwon Health and Beyond Blue. Leanne is a former Deputy Chancellor of Monash University.
|Mr Andrew Mark Rendle Dutton||Non-Executive Director||Apr 2021||
Mr Andrew Mark Rendle Dutton
Mr Dutton has 30 years of management, business development and technology experience across Australia, Asia and Europe. Andrew is the current Chair of Land Registry Services and was recently an Advisor to FinancialForce APJ. He has had Chief Executive Officer and Board experience globally and within Australia. Andrew's former roles include Chair of NVOI Pty Ltd and SAI Global Pty Ltd; Chief Executive Officer at Land Registry Services and Integrated Research Limited; Managing Director of the Asia Pacific/Japan region for VMware Inc.; and senior executive positions at IBM, Computer Associates, BEA Systems Inc., Lend Lease and Norwich Union Financial Services Group including roles as CFO, CMO, CRO and Divisional Heads. At IBM, Andrew was elected to the Worldwide Senior Leadership Team.
|Mr Mark Haberlin||Non-Executive Director||Apr 2021||
Mr Mark Haberlin
Mr Haberlin has over 25 years of audit, risk management, capital transactions and mergers and acquisitions experience across industries including healthcare, real estate and financial services. Mark is the Lead Independent Director and Chair of the Audit & Risk Committee of Abacus Property Group. Mark is also an Independent Non-Executive Director and the Chair of the Audit & Risk Committee of Laybuy Group Limited. Previously, Mark was the Chair of PwC Australia and PwC's Public Reporting Panel, as well as a Director of the European Australia Business Council and PwC Asia Pacific.
|Mr Michael Thomas Alscher||Non-Executive Chairman,Non-Executive Director||Dec 2020||
Mr Michael Thomas Alscher
Non-Executive Chairman,Non-Executive Director
Mr Alscher is the Managing Partner and founder of Crescent, an Australian private equity investment firm, focusing on high growth companies and certain industry sectors such as healthcare. Michael is the current Chair of Cardno Limited, National Dental Care Limited, National Home Doctor Service Pty Ltd and is a Non-Executive Director of Clearview Wealth Limited. Michael's former director roles include Chair of Cover-More Group Limited, LifeHealthcare Group Limited and Director of Metro Performance Glass Limited. Prior to founding Crescent in 2000, Michael was a strategy consultant at Bain International and LEK Partnership as well as holding several senior operating roles.
|Mr Nathanial Jonothan Thomson||Non-Executive Director||Dec 2020||
Mr Nathanial Jonothan Thomson
Mr Thomson is a Partner at Crescent, an Australian private equity investment firm. Nathanial has over 20 years of experience in strategy consulting, private equity and investment banking. He has consulting experience from his prior role at McKinsey & Co. Nathanial is a current Director of Cardno Limited, National Dental Care Limited, Clearview Wealth Limited and National Home Doctor Service Pty Ltd. Nathanial's former director roles include Deputy Chair of Cover-More Group Limited and a Non-Executive Director of Metro Performance Glass Limited.
|Ms Melinda Leigh McGrath||Chief Executive Officer,Executive Director||Dec 2020||
Ms Melinda Leigh McGrath
Chief Executive Officer,Executive Director
Ms McGrath has more than 30 years' experience in healthcare with over 20 years of experience in chief executive roles and over 13 years of experience in pathology CEO roles. Melinda has been involved in the organisation's transformation, building ACL's scale and operational performance improvement over the past six years, overseeing the integration of Healthscope's Australian pathology business, St John of God Health Care's pathology business, Perth Pathology and SunDoctors. Melinda was Chief Executive Officer of QML Pathology (part of Healius) from 2008 to 2015, where she developed five QML brands and established Tasmania Medical Laboratories. Prior to that, Melinda held various chief executive roles at private regional and tertiary referral hospitals in Queensland including The Sunshine Coast Private Hospital, St Andrew's War Memorial Hospital and St Stephens Private Hospital. Melinda has held board member positions at Metro North Hospitals and Health Service including Royal Brisbane, Prince Charles, Redcliffe, Caboolture and related health services, and a superannuation fund, UC Super.
|Ms Eleanor Padman||Company Secretary||N/A|
ACL directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
|25/05/21||Melinda McGrath||Issued||247,252||$3.64||$899,997||Issue of securities|
The current holdings of ACL directors.
|Director||Last Notice||Direct Shares||Indirect Shares||Options||Convertibles|
No Substantial Shareholders for ACL in our database.
12 month transaction history compiled from ASX announcements.
|Date||Name||Bought||Previous %||New %|
|02-07-21||Ethical Partners Funds Management Pty Ltd||5,800,142||5.75||8.62|
|19-05-21||Ethical Partners Funds Management Pty Ltd||11,598,277||--||5.75|
|14-05-21||Crescent Capital Partners Management Pty Limited||134,292,481||--||91.15|
|14-05-21||ACL SaleCo Limited||49,346,290||--||33.49|
12 month transaction history compiled from ASX announcements.
|Date||Name||Sold||Previous %||New %|
|19-05-21||ACL SaleCo Limited||49,346,290||33.5||--|
|18-05-21||Crescent Capital Partners Management Pty Limited||44,610,563||91.2||44.4|
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.